Hubei Goto Biopharm Group Co., Ltd. (SHE:300966)
China · Delayed Price · Currency is CNY 24.92
+0.42 (1.71%)
Aug 4, 2026, 3:04 PM CST
Hubei Goto Biopharm Group Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 2,846 | 2,266 | 1,859 | 2,648 | 3,112 | 4,729 | |
Market Cap Growth | -7.46% | 21.86% | -29.78% | -14.93% | -34.18% | - |
Enterprise Value | 4,170 | 3,527 | 2,838 | 3,321 | 3,500 | 4,781 |
Last Close Price | 24.92 | 19.66 | 16.11 | 22.91 | 26.93 | 40.73 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | - | - | - | 115.10 | 77.42 | 60.37 |
PS Ratio | 4.53 | 3.74 | 3.47 | 4.68 | 5.15 | 8.00 |
PB Ratio | 3.13 | 2.49 | 1.83 | 2.59 | 3.17 | 5.71 |
P/TBV Ratio | 3.67 | 2.93 | 2.13 | 2.94 | 3.52 | 6.07 |
P/OCF Ratio | 40.71 | 55.22 | - | 38.86 | - | 81.52 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 6.63 | 5.82 | 5.29 | 5.86 | 5.79 | 8.09 |
EV/EBITDA Ratio | 48.74 | 57.72 | 100.45 | 62.18 | 50.18 | 55.11 |
EV/EBIT Ratio | - | - | - | 123.29 | 77.00 | 74.15 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 1.45 | 1.43 | 1.12 | 0.77 | 0.79 | 0.20 |
Debt / EBITDA Ratio | 15.41 | 21.24 | 39.68 | 14.25 | 10.60 | 1.84 |
Net Debt / Equity Ratio | 1.36 | 1.33 | 0.98 | 0.59 | 0.32 | -0.06 |
Net Debt / EBITDA Ratio | 14.53 | 19.86 | 35.05 | 11.31 | 4.54 | -0.56 |
Net Debt / FCF Ratio | -30.90 | -9.68 | -2.98 | -1.77 | -0.73 | 1.47 |
Asset Turnover | 0.22 | 0.22 | 0.21 | 0.25 | 0.37 | 0.59 |
Inventory Turnover | 1.20 | 1.24 | 1.12 | 1.09 | 1.16 | 1.56 |
Quick Ratio | 0.37 | 0.34 | 0.44 | 0.61 | 1.26 | 1.37 |
Current Ratio | 0.99 | 0.94 | 0.95 | 1.27 | 2.11 | 2.58 |
Return on Equity (ROE) | -8.30% | -8.49% | -3.11% | 2.12% | 4.37% | 11.41% |
Return on Assets (ROA) | -1.03% | -1.20% | -0.35% | 0.74% | 1.73% | 4.00% |
Return on Invested Capital (ROIC) | -2.24% | -2.63% | -0.81% | 1.84% | 4.38% | 8.12% |
Return on Capital Employed (ROCE) | -2.30% | -2.70% | -0.70% | 1.50% | 3.00% | 7.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | -2.50% | -3.24% | -1.48% | 0.87% | 1.29% | 1.66% |
FCF Yield | -1.41% | -5.53% | -17.87% | -12.88% | -13.88% | -0.70% |
Dividend Yield | 0.18% | 0.23% | - | 0.07% | - | 0.33% |
Payout Ratio | - | - | - | 26.49% | 66.92% | 9.67% |
Buyback Yield / Dilution | -1.58% | 0.29% | 0.05% | -0.13% | -8.77% | -22.87% |
Total Shareholder Return | -1.38% | 0.52% | 0.05% | -0.06% | -8.77% | -22.54% |